Analysis of Clinical Treatment Efficiency for 179 Geriatric Women with Stage I or II Cervical Carcinoma

OBJECTIVE To evaluate the efficiency of surgery plus radiotherapy and chemotherapy versus radiotherapy plus chemotherapy in the treatment of older patients with stage I or II cervical carcinoma and to seek suitable treatment for such patients. METHODS The clinical data of 179 elderly women with stage la or lib cervical cancer were analyzed retrospectively. One hundred and thirty-four cases underwent radical hysterectomy followed by adjuvant radiotherapy and/or chemotherapy (Group 1). Forty-five cases underwent radiation therapy plus adjuvant chemotherapy (Group 2). RESULTS The 5-year survival rates in group 1 and group 2 were 78.3% and 49.1%(P=0.04), respectively. The incidence of complications in group1 was 47.0%. Three patients died of complications after radical hysterectomy. The incidence of complications in group 2 was 75.6%. CONCLUSION Elderly patients with stage I or II cervical carcinoma should receive an operation if possible. In addition they should receive adjuvant treatments according to their personal conditions, and be treated with appropriate adjuvant chemo-and/or radiotherapy.     

High-risk endometrial cancer may be benefit from adjuvant radiotherapy plus chemotherapy

Objective:To present patterns of practice and outcomes in the adjuvant treatment of intermediate-and high-risk endometrial cancer.Methods:Retrospective data on 224 women with intermediate-risk and high-risk endometrial cancer from 1999 to 2006 were reviewed.All patients underwent surgical staging.Patterns of adjuvant treatment,consisting of pelvic radiotherapy,chemotherapy,and radiotherapy plus chemotherapy,were assessed.The 3and 5-year disease-specific survival(DSS) rates were calculated using the Kaplan-Meier method.Results:The difference in 5-year DSS rate was statistically significant between adjuvant group and non-adjuvant group(80.65% vs.63.80%,P=0.040).In 110 high-risk patients who underwent adjuvant treatment,both 5-year DSS rate and recurrent rate were significantly different in combined radiotherapy and chemotherapy group compared with radiotherapy alone and chemotherapy alone groups(DSS rate,P=0.049;recurrent rate,P=0.047).In 83 intermediate-risk women who underwent adjuvant treatment,there was no significant difference in 5-year DSS rate and recurrence rate among the combined radiotherapy and chemotherapy,radiotherapy alone and chemotherapy alone groups(DSS rate,P=0.776;recurrent rate,P=0.937).Conclusions:Adjuvant radiotherapy plus chemotherapy is associated with a higher 5-year DSS rate and lower recurrence rate compared with radiotherapy alone and chemotherapy alone in high-risk endometrial cancer patients.Patients with intermediate-risk endometrial cancer may be not likely to benefit from adjuvant combined radiotherapy and chemotherapy.     

A Prospective Randomized Study of Adjuvant Chemotherapy in Completely Resected Stage III-N2 Non Small Cell Lung Cancer

Objective: To evaluate the effect of postoperative adjuvant chemotherapy on survival after complete resection of stage III-N2 non-small-cell lung cancer. Methods: From Jan. 1999 to Dec. 2003, one-hundred and fifty patients, who were diagnosed as stage III-N2 non-small cell lung cancer after operation, were randomly devided into chemotherapy group and control group. The former received four cycles of chemotherapy with NVB (25 mg/m2, D1, D5)/paclitaxel (175 mg/m2, D1) and Carboplatin (AUC=5, D1). Results: In chemotherapy group, 75.8% (68/79) of patients had finished the 4 cycles of chemotherapy and no one died of toxic effects of chemotherapy. Twenty-five percent of the patients had grade 3?4 neutropenia and 2% had febrile neutropenia. The median survival for the entire 150 patients was 879 d, with 1-year survival rate of 81%, 2-year survival rate of 59% and 3-year survival rate of 43%. There was no significant difference in median survival between chemotherapy and control group (897 d vs 821 d, P=0.0527), but there was significant difference in the 1-year and 2-year overall survival (94.71%, 76.28% vs 512 d, P=0.122), but there was significant difference in the 2-year survival rate between two groups with brain metastases (66.7% vs 37.6% P<0.05). The median survival after brain metastasis appeared was 190 days. Conclusion: Postoperative adjuvant chemotherapy does not significantly improve median survival among patients with completely resected stage II-N2 non-small-cell lung cancer, but significantly improves the 1-year and 2-year overall survival. It neither decreases the incidence of brain metastasis but put off the time of brain metastasis.     

Investigation of the Effect of Neoadjuvant Chemotherapy on Stage Ⅱ Breast Cancer

OBJECTIVE To investigate the effect of neoadjuvant chemotherapy in treatment of Stage Ⅱ breast cancer. METHODS The data from 113 patients with breast cancer of the same pathologic type in Stage Ⅱ,during the period of 1995 to 2001,were analyzed retrospectively.Among the patients,47 were treated with neoadjuvant chemotherapy,and 66 received no adjuvant therapy before surgery（control group）.After the patients of the neoadjuvant chemotherapy group had received 2 courses of chemotherapy with the CMF regimen,the surgical procedure was conducted. RESULTS Complete remission（CR）was attained in 9 of the 47 cases receiving neoadjuvant chemotherapy and partial remission（PR）was reached for 22 cases.The rate of breast-conserving surgery was enhanced from 22.73%to 46.81%（P〈0.05）in the neoadjuvant treatment group. There was no difference in the 5-year overall survival（OS）and disease-free survival（DFS）rate between the two groups（P〉0.05）,but the 5-year OS and DFS of the cases with clinical tumor remission was higher compared to the control group（P〈0.05）. CONCLUSION Neoadjuvant chemotherapy can enhance the rate of breast conservation for Stage Ⅱ breast cancer and may improve the prognosis of the cases with clinical remission.     

TTC及FTC方案新辅助化疗治疗乳腺癌的疗效分析

Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TIC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TTC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P=0.000), but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P=0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TIC ann and 11.2 % in CTF ann (P=0.491). Conclusion TIC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from 9eoadjuvant taxane and anthracycline chemotherapy.     

Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma

Objective:No standard postoperative adjuvant chemotherapy has ever been established in node-positive esophageal squamous cell carcinoma (ESCC).This is a study to explore the effect of postoperative paclitaxel (PTX) and cisplatin (DDP) in lymph node-positive,completely resected thoracic ESCC patients.Methods:We conducted a prospective phase Ⅱ trial.Patents had pathologically node-positive thoracic ESCC with negative margins.Outcomes of disease-free survival (DFS) and overall survival (OS) were compared with a matched historical control cohort.The postoperative chemotherapy regimen consisted of 4 to 6 cycles of PTX 150 mg/m2 administered intravenously on d 1 followed by DDP 50 mg/m2 on d 2 every 14 d.Results:Forty-three patients were accrued from December 2007 to May 2012 at Cancer Hospital of Chinese Academy of Medical Sciences for adjuvant chemotherapy.The historical control group consisted of 80 patients who received complete resection but no adjuvant chemotherapy during the same period of time.Of the 43 patients with adjuvant chemotherapy,37 (86.0％) patients completed 4 to 6 cycles of chemotherapy.The 3-year DFS rates were 56.3％ in the adjuvant group and 34.6％ in the control group (P=0.006).The 3-year OS rates were 55.0％ in the adjuvant group and 37.5％ in the control group (P=0.013).Multivariate analysis revealed that postoperative chemotherapy was the significant predictor for improved OS (P=0.005).Conclusions:Biweekly adjuvant PTX and DDP might improve 3-year DFS and OS in lymph node-positive,curatively resected thoracic ESCC patients.These conclusions warrant further study in randomized phase Ⅲ clinical trials.     

TTC及FTC方案新辅助化疗治疗乳腺癌的疗效分析

Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TIC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TTC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P=0.000), but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P=0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TIC ann and 11.2 % in CTF ann (P=0.491). Conclusion TIC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from 9eoadjuvant taxane and anthracycline chemotherapy.     

TTC及FTC方案新辅助化疗治疗乳腺癌的疗效分析

Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TIC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TTC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P=0.000), but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P=0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TIC ann and 11.2 % in CTF ann (P=0.491). Conclusion TIC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from 9eoadjuvant taxane and anthracycline chemotherapy.     

TTC及FTC方案新辅助化疗治疗乳腺癌的疗效分析

Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TIC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TTC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P=0.000), but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P=0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TIC ann and 11.2 % in CTF ann (P=0.491). Conclusion TIC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from 9eoadjuvant taxane and anthracycline chemotherapy.     

TTC及FTC方案新辅助化疗治疗乳腺癌的疗效分析

Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TIC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TTC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P=0.000), but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P=0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TIC ann and 11.2 % in CTF ann (P=0.491). Conclusion TIC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from 9eoadjuvant taxane and anthracycline chemotherapy.     

胃癌患者采用腹腔镜辅助全胃切除术治疗的疗效及预后分析

目的 探讨胃癌腹腔镜辅助全胃全切术后实施不同消化道重建方式对患者术后消化吸收功能的影响.方法 将100例胃癌患者按照随机数字表法分为对照组(行空肠食管Roux-en-y吻合术)与观察组(行"P"形空肠袢空肠食管Roux-en-y吻合术),各50例.比较两组患者并发症、术后营养状况;同时统计两组患者平均手术时间、术中出血量.结果 两组患者术中并发症及术后腹泻、反流性食管炎发生率比较,无统计学意义,P>0.05;两组术后腹胀、倾倒综合征发生率比较,差异有统计学意义,P<0.05.观察组ALB、RBC、TP、HGB水平明显高于对照组,差异具有统计学意义,P<0.05.观察组平均手术时间、术中平均出血量分别为(2.5±0.4)h、(317.5±32.6)ml,与对照组[(3.4±0.4)h、(318.1±33.0)ml]比较,其中手术时间比较,差异显著,P<0.05;而出血量比较,差异无统计学意义,P>0.05.结论 于腹腔镜辅助全胃全切术治疗胃癌患者后实施"P"形空肠袢空肠食管Roux-en-y吻合术,有利于患者康复.     

全胃切除功能性间置空肠代胃术72例临床分析

目的：探讨功能性间置空肠代胃消化道重建在全胃切除术后的应用价值.方法：回顾性分析2006年1月-2011年12月施行全胃切除功能性间置空肠代胃术72例患者的临床资料.结果：全组无手术死亡和吻合口瘘发生.随访12个月至24个月,部分病例出现轻度反流性食管炎,代胃容量300ml以上,排空时间30-100min.术后生活质量有所提高.结论：功能性间置空肠代胃术是一种安全可靠、效果满意的消化道重建手术方式.     

全胃切除术后两种消化道重建术式的比较

目的探讨全胃切除术后两种消化道重建术式手术操作时间、病人术后生活质量的影响。方法对2003年1月-2007年6月我院施行全胃切除术的218例病人的临床资料进行回顾性分析。全胃切除后消化道重建分别采用P型空肠袢食管空肠Roux—en—Y吻合术（PR法）（A组,96例）和改良空肠间置代胃吻合术（FJI法）（B组,44例）。记录术中消化道重建时间、术后12个月营养状况和胃肠道症状（GSRS）评分等。结果消化道重建术所需时间两组比较,差异无统计学意义（P〉0．05）。术后12个月B组与A组比较,进食量明显增加（P〈0．05）,而GSRS评分降低（P〈0．05）。术后12个月B组体重恢复较A组更佳,差异有统计学意义（P〈0．05）。结论改良空肠间置代胃吻合术有利于维持病人术后生活质量,在每天进食量及体重恢复方面改良空肠间置代胃吻合术优于P型空肠袢食管空肠Rottx—en—Y吻合术。     

改良空肠间置术对食管胃交界部腺癌的临床应用价值

目的探讨SiewertⅡ/Ⅲ型食管胃交界部腺癌（AEG）患者根治性近端胃切除术后,两种消化道重建方式对患者术后生活质量的影响。方法将70例根治性近端胃切除术后SiewetⅡ/Ⅲ型AEG患者,消化道重建,随机分为两组：实验组（改良空肠间置组）35例,对照组（食管残胃吻合组）35例。观察两组患者术后食管炎的发生情况及术后1年的营养状况。结果术后实验组反流性食管炎发生率明显低于对照组（P〈0.01）,术后1年实验组血红蛋白及总蛋白水平均高于对照组,体重下降幅度小于对照组（P〈0.05）。结论改良空肠间置术应用于Ⅱ/Ⅲ型AEG患者术后消化道重建,可提高患者术后生活质量,值得临床推广应用。     

间置空肠代胃术的临床应用(附202例报告)

目的：探讨间置空肠代胃术在不同手术方法中的应用及其临床效果。方法：回顾性分析1991年1月至2005年8月间,本院实施间置空肠代胃术共202例,其中包括功能性间置空肠代胃术,p型间置空肠代胃术,胆总管间置空肠架桥引流术,改良间置空肠代胃术,近端胃次全间置空肠移植术等。结果：本组病例术后无明显返流性食管炎,倾倒综合征发生,亦无明显吻合口瘘情况。结论：间置空肠代胃术操作简捷,易于掌握,临床应用效果良好。     

全胃切除后消化道重建的前瞻性随机对照研究

目的　探讨全胃切除术后消化道重建的合理术式。方法　以 12例健康人为对照 ,对12 0例胃癌行全胃切除后 ,随机按食管空肠Roux y吻合 (A组 )、食管空肠“P”袢 +Roux y吻合 (B组 )、食管空肠Hunt Lawrence吻合 (C组 )及食管空肠原位间置代胃术 (D组 )等 4种术式行消化道重建 ,并比较其术后生活质量、预后营养指标 (PNI)指数、体重、血液营养学指标、胃肠激素水平、免疫功能 ,并以此判断各术式的优劣。结果　D组在PNI指数、体重变化和血液营养学指标上均优于A、B、C组(P <0 .0 5 ) ;D组餐后 30min胆囊收缩素 (CCK)水平及NK细胞、CD4 细胞、CD8细胞以及CD4 CD8值与对照组相似 ,亦均优于A、B、C组 (P <0 .0 5 ) ,差异有具著性。结论　食管空肠原位间置代胃术是一较合理的消化道重建术式。其空肠“P”字型构造具有代胃的功能 ;食糜通过十二指肠刺激CCK等胃肠激素的分泌 ,有利于消化及营养的吸收 ;仅切断一端空肠以及适度大小的代胃 ,保持了空肠及系膜原来的连系 ,既简化了手术 ,又保证了间置代胃空肠的血运 ,吻合口无缺血坏死之忧。     

Beneficial effects of jejunal continuity and duodenal food passage after total gastrectomy: A retrospective study of 704 patients

Aim

To evaluate effects of reconstruction procedures on post-operative outcomes and nutritional status after total gastrectomy.

Methods

The study group comprised 704 consecutive patients with gastric cancer who underwent total gastrectomy between December 1985 and December 2003. Six alimentary reconstruction procedures were performed, including jejunal continuity [Braun, modified Braun I and II and functional jejunal interposition (FJI)] and jejunum transection [“P” Roux-en-Y and “P” jejunal interposition (PJI)]. The duodenal food passage was maintained only by FJI and PJI. We evaluated the time interval to restore food intake after surgery and the incidence of complications and nutritional status for 12 months.

Results

Patients who received jejunum transection required 7.8 ± 2.5 days and 11.9 ± 4.9 days to restore liquid and semi-liquid food intake, respectively, which reduced to 3.9 ± 2.1 days for liquid and 7.9 ± 3.9 days for semi-liquid food intake by jejunum continuity. The incidence rates of reflux esophagitis and Roux-en-Y syndrome in patients receiving jejunum transection were 23.5% and 42.4%, respectively, which were decreased to 9.35% and 14.7%, respectively, by jejunal continuity. Furthermore, prognostic nutrition index score of patients receiving the procedures maintaining duodenal food passage (52.9 ± 10.9) was higher than that of patients without the duodenal food passage (46.7 ± 8.2).

Conclusion

Jejunal continuity and duodenal food passage showed beneficial effects on clinical outcomes after surgery. Among these six procedures, FJI was the only procedure to combine the benefits of jejunal continuity and maintaining the duodenal food passage, indicating that FJI has potential clinical application to improve the quality of patient's life after total gastrectomy.     

空肠间置代食管术在食管癌贲门癌外科治疗中的临床应用

目的探讨空肠间置代食管术在食管癌贲门癌外科治疗中的临床应用价值。方法采用空肠间置代食管术治疗38例食管癌贲门癌患者。结果 38例手术均成功,术后并发症少,无手术死亡者,术后恢复良好。结论空肠间置代食管重建消化道术式,对食管癌贲门癌的疗效确切,并发症少,术后患者生活质量好,值得推广应用。     

全胃切除连续间置空肠代胃消化道重建术

[目的]探讨连续间置空肠代胃消化道重建术在全胃切除后的应用价值.[方法]对2000年1月至2002年3月间26例全胃切除连续间置空肠代胃术的临床资料进行分析.[结果]全组病人无手术死亡和吻合口瘘发生.随访12个月至25个月,平均17.4个月.其中钡餐检查11例,代胃容量均在300ml以上,排空时间为30min～120 mm.术后6个月、12个月出现反流性食管炎分别为6例和2例.与术前相比,术后生活质量有所提高.[结论]连续间置空肠代胃术是全胃切除消化道重建的理想术式,手术操作简便省时,可取得较好的生活质量.     

全胃切除术后FJI消化道重建的临床研究

Objective To investigate the optimum reconstruction after total gastrectomy for malignant disease, especially the necessity of gastric substitute and duodenal passage. Methods Among the 459 total gastrectomy cases, 6 kinds of reconstructions had been used, including Braun, modified Braun I (mBraun I), modified Braun II (mBraun II), Roux-en-Y, “P” jejunal interposition (PJI) and functional jejunal interposition (FJI). Postoperative complains, body weight, food intake, serum nutritional paraments, complete blood count, half-emptying time of the gastric substitute, PNI, Visick index were evaluated one year after surgery. Results As compared with Braun group, the mBraun I, II and Roux-en-Y groups which had some kinds of gastric substitute showed less reflux esophagitis and higher serum total protein (P<0.01). As compared with mBraun I, II, Roux-en-Y, PJI and FJI groups which had duodenal passage showed better body weight, higher nutritional paraments and PNI (P<0.05). Conclusion It is essential to construct a gastric substitute and maintain the food chyme flowing through the duodenum after total gastrectomy, and the FJI is a better choice in this study.